Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: A pilot study

European Radiology

Volumn 22, Issue 3, 2012, Pages 642-653

  Dahlqvist Leinhard, O ^a   Dahlstrom N ^a   Kihlberg, J ^a   Sandstrom P ^a   Brismar, T B ^b   Smedby, O ^a   Lundberg, P ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dynamic contrast enhanced MRI; Gadobenate Dimeglumine; Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid; Liver; Pharmacokinetics

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOXETIC ACID;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HEPATOBILIARY DISEASE; HUMAN; LIVER PARENCHYMA; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SPLEEN;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SPLEEN; TREATMENT OUTCOME;

EID: 84856623122     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2302-4     Document Type: Article

References (24)

1. N Tsuda M Okada T Murakami 2010 New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI Eur J Radiol 73 137 142 19026502 10.1016/j.ejrad.2008. 09.036
2. C Planchamp CM Pastor L Balant CD Becker F Terrier M Gex-Fabry 2005 Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA Invest Radiol 40 11 705 714 16230903 10.1097/01.rli.0000183053.08921.2b 1:CAS:528: DC%2BD2MXhtFajtL3L (Pubitemid 41546837)
3. A Spinazzi V Lorusso G Pirovano M Kirchin 1999 Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers Acad Radiol 6 5 282 291 10228617 10.1016/S1076-6332(99)80451-6 1:STN:280:DyaK1M3ksFejsw%3D%3D (Pubitemid 32673373)
4. N Tsuda M Okada T Murakami 2007 Potential of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging Invest Radiol 42 4 242 247 10.1097/01.rli.0000258058.44876.a5 17351431 10.1097/01.rli.0000258058.44876.a5 1:CAS:528:DC%2BD2sXislChu78%3D (Pubitemid 46398863)
5. C Planchamp M Gex-Fabry CD Becker CM Pastor 2007 Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers Invest Radiol 42 7 513 521 10.1097/RLI.0b013e318036b450 17568274 10.1097/RLI. 0b013e318036b450 (Pubitemid 46955246)
6. U Motosugi T Ichikawa H Sou, et al. 2009 Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30 5 1042 1046 10.1002/jmri.21956 19856436 10.1002/jmri.21956
7. U Motosugi T Ichikawa L Tominaga, et al. 2009 Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 19 11 2623 2629 10.1007/s00330-009-1467-6 19471935 10.1007/s00330-009-1467-6
8. Yamada A, Hara T, Li F et al (2011) Quantitative Evaluation of Liver Function with Use of Gadoxetate Disodium-enhanced MR Imaging. Radiology. doi: 10.1148/radiol.11100586
9. A Jackson 2004 Analysis of dynamic contrast enhanced MRI Br J Radiol 77 Spec No 2 S154 166 15677357 10.1259/bjr/16652509 (Pubitemid 40277715)
10. R Treier A Steingoetter M Fried W Schwizer P Boesiger 2007 Optimized and combined T1 and B1 mapping technique for fast and accurate T1 quantification in contrast-enhanced abdominal MRI Magn Reson Med 57 3 568 576 10.1002/mrm.21177 17326175 10.1002/mrm.21177 (Pubitemid 46385867)
11. W Huang Y Wang DM Panicek LH Schwartz JA Koutcher 2009 Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data Magn Reson Imaging 27 6 852 858 10.1016/j.mri.2009.01.020 19282123 10.1016/j.mri.2009.01.020 1:CAS:528:DC%2BD1MXnsV2ksrk%3D
12. RN Pugh IM Murray-Lyon JL Dawson MC Pietroni R Williams 1973 Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 8 646 649 4541913 10.1002/bjs.1800600817 1:STN:280:DyaE3s3jsVWqsw%3D%3D
13. PS Kamath RH Wiesner M Malinchoc, et al. 2001 A model to predict survival in patients with end-stage liver disease Hepatology 33 2 464 470 11172350 10.1053/jhep.2001.22172 1:STN:280:DC%2BD3M7kvVOqug%3D%3D (Pubitemid 32119037)
14. CM de Bazelaire GD Duhamel NM Rofsky DC Alsop 2004 MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results Radiology 230 3 652 659 10.1148/radiol.2303021331 14990831 10.1148/radiol.2303021331 (Pubitemid 38252858)
15. RR Ernst WA Anderson 1966 Application of fourier transform spectroscopy to magnetic resonance Review of Scientific Instruments 37 1 93 102 10.1063/1.1719961 1:CAS:528:DyaF28Xjt1egsQ%3D%3D
16. J Pintaske P Martirosian H Graf, et al. 2006 Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla Invest Radiol 41 3 213 221 10.1097/01.rli.0000197668.44926.f7 16481903 10.1097/01.rli.0000197668. 44926.f7 (Pubitemid 44406181)
17. DG Levitt 2003 The pharmacokinetics of the interstitial space in humans BMC Clin Pharmacol 3 3 10.1186/1472-6904-3-3 12890292 10.1186/1472-6904-3-3 (Pubitemid 38751346)
18. D Stricker 2008 BrightStat.com: free statistics online Comput Methods Programs Biomed 92 1 135 143 10.1016/j.cmpb.2008.06.010 18653259 10.1016/j.cmpb.2008.06.010
19. C Thomsen P Christoffersen O Henriksen E Juhl 1990 Prolonged T1 in patients with liver cirrhosis: an in vivo MRI study Magn Reson Imaging 8 5 599 604 2082130 10.1016/0730-725X(90)90137-Q 1:STN:280:DyaK3M7os1Olug%3D%3D (Pubitemid 20321976)
20. KJ Van Lom JJ Brown WH Perman JC Sandstrom JK Lee 1991 Liver imaging at 1.5 tesla: pulse sequence optimization based on improved measurement of tissue relaxation times Magn Reson Imaging 9 2 165 171 2034049 10.1016/0730-725X(91) 90006-8
21. JB Warntjes OD Leinhard J West P Lundberg 2008 Rapid magnetic resonance quantification on the brain: optimization for clinical usage Magn Reson Med 60 2 320 329 10.1002/mrm.21635 18666127 10.1002/mrm.21635 1:STN:280: DC%2BD1cvptlKitQ%3D%3D
22. B Hamm T Staks A Muhler, et al. 1995 Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging Radiology 195 3 785 792 7754011 1:STN:280:DyaK2M3ntlGrsg%3D%3D
23. T Tajima H Takao H Akai, et al. 2010 Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging J Comput Assist Tomogr 34 3 362 366 10.1097/RCT.0b013e3181cd330400004728-201005000-00007 20498536 10.1097/RCT.0b013e3181cd3304
24. MS Lee JY Lee SH Kim, et al. 2011 Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI J Magn Reson Imaging 33 1 149 159 10.1002/jmri.22429 21182133 10.1002/jmri.22429